Read more about the article Radiopharmaceutical Imaging and Dosimetry (Rapid®) receives FDA clearance for its first 3D-RD™ product: 3D-RD-S

Radiopharmaceutical Imaging and Dosimetry (Rapid®) receives FDA clearance for its first 3D-RD™ product: 3D-RD-S

Baltimore, Maryland – Rapid is pleased to announce that it has received FDA 510(k) market clearance for its first software product: 3D-RD-S, the first web-browser based application that implements the MIRD Schema to perform radiopharmaceutical dosimetry calculations.

Continue ReadingRadiopharmaceutical Imaging and Dosimetry (Rapid®) receives FDA clearance for its first 3D-RD™ product: 3D-RD-S
Read more about the article Rapid receives a $2.0M NIH Phase II Grant, Development and Validation of a Collaborative Web/Cloud-Based Dosimetry System for Radiopharmaceutical Therapy.
Closeup photo of two doctors analyzing a medical result on a computer screen

Rapid receives a $2.0M NIH Phase II Grant, Development and Validation of a Collaborative Web/Cloud-Based Dosimetry System for Radiopharmaceutical Therapy.

Rapid receives a $2.0M NIH Phase II Grant, Development and Validation of a Collaborative Web/Cloud-Based Dosimetry System for Radiopharmaceutical Therapy.

Continue ReadingRapid receives a $2.0M NIH Phase II Grant, Development and Validation of a Collaborative Web/Cloud-Based Dosimetry System for Radiopharmaceutical Therapy.
Read more about the article Rapid receives a $299k/$2.0M NCI Fast track Phase I/II Contract, Targeted Radionuclide Therapy of Metastatic Liver Cancer: Patient Specific Optimization.
Doctors attending to a patient on a medical machinery

Rapid receives a $299k/$2.0M NCI Fast track Phase I/II Contract, Targeted Radionuclide Therapy of Metastatic Liver Cancer: Patient Specific Optimization.

Rapid receives a $299k/$2.0M NCI Fast track Phase I/II Contract, Targeted Radionuclide Therapy of Metastatic Liver Cancer: Patient Specific Optimization.

Continue ReadingRapid receives a $299k/$2.0M NCI Fast track Phase I/II Contract, Targeted Radionuclide Therapy of Metastatic Liver Cancer: Patient Specific Optimization.